Both in Biotechnology
Biogen vs Halozyme Therapeutics
Over the past year BIIB returned +67.5% and HALO returned +97.7%; their daily moves had a correlation of 0.28.
BIIB +67.5% HALO +97.7%Growth of $1, one year, split-adjusted
| Metric | BIIB | HALO |
|---|---|---|
| Price | $253.62 | $130.91 |
| Market cap | $37.49B | $14.86B |
| Today | +1.59% | −0.21% |
| 1 month | +13.8% | +22.4% |
| 6 months | +35.6% | +104.7% |
| Year to date | +44.1% | +94.5% |
| 1 year | +71.5% | +100.6% |
| Revenue growth (YoY) | +10.6% | +47.7% |
| Gross margin | 73.3% | 83.5% |
| Net margin | −0.7% | 47.8% |
| P/E (TTM) | 107.9× | 35.9× |
| Price / sales | 3.6× | 8.9× |
| Net cash | -$6.39B | -$1.92B |
| Dividend yield | — | — |
| Volatility (60d) | 27.9% | 45.9% |
| Short % of float | 3.7% | 12.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).